Pharmacotherapy for Mild Persistent Asthma Essay

Pharmacotherapy for Mild Persistent Asthma Essay

Pharmacotherapy for Mild Persistent Asthma in a 15 Year-Old Hispanic Female

The specific goals of pharmacotherapy for patient M.L. with mild persistent asthma include the following (Healthwise, 2019; Tiziani, 2017):

  1. Preventing exacerbation of symptoms that lower the quality of life. These include dyspnea with or without exercise and coughing.
  2. Preservation of lung function. Pharmacotherapy aims at preventing the lung parenchyma from being destroyed.
  • Preventing repeat attacks. Repeat attacks render the patient unable to function. Pharmacotherapy for Mild Persistent Asthma Essay.
  1. Enabling patient M.L. to participate in her daily activities and sporting role. Without pharmacotherapy, patient M.L. would not be able to perform her daily functions such as learning or playing soccer.
  2. Giving the best symptom relief with the least amount of side effects. It is desirable to have medications that are efficacious with very few side effects that bother the patient.

The drug therapy that a CNP would likely prescribe for patient M.L. is:

  1. A short-acting beta-agonist (SABA) such as ventolin (albuterol) in the form of an inhaler. It is a bronchodilator and she will inhale two puffs orally every time she has an attack or impending attack.
  2. An oral corticosteroid such as methylprednisolone (Medrol) 4 mg orally every day (Katzung, 2018; Rosenthal & Burchum, 2018).


Because the asthma is mild, it makes sense to control the symptoms with just a SABA instead of a long-acting beta-agonist (LABA). But to reduce the inflammability of the mucous membranes and prevent the manifestation of symptoms, adding a corticosteroid makes more clinical sense and is actually evidence-based (Katzung, 2018; Rosenthal & Burchum, 2018).

The parameters for monitoring the success of therapy include the frequency of episodes while on treatment, the ability to carry on with playing soccer, and the occurrence of side effects. By taking cognizance of these parameters, it will be possible to determine whether the pharmacotherapy has been a success or not. The age-appropriate health promotion for patient M.L. includes avoidance of environmental allergens such as pollen, dust, and smoke as well as always having her albuterol inhaler within reach.


Healthwise (June 9, 2019). Asthma treatment goals.,near%20the%20personal%20best%20measurement. Pharmacotherapy for Mild Persistent Asthma Essay.

Katzung, B.G. (Ed) (2018). Basic and clinical pharmacology, 14th ed. McGraw-Hill Education.

Rosenthal, L.D., & Burchum, J.R. (2018). Lehne’s pharmacotherapeutics for nurse practitioners and physician assistants. Elsevier.

Tiziani, A. (2017). Havard’s nursing guide to drugs, 8th ed. Elsevier

  1. L. is a 15-year-old Hispanic female who plays soccer for her school team. She has noticed that when running, she sometimes has trouble catching her breath. She also reports an increased runny nose and itchy eyes. She has a frequent dry cough and is awakened with coughing spells at least four times a week. Her mother and father have seasonal allergies and her mother has asthma. This morning she woke up and heard “funny sounds” when she took a breath. Her coughing increased when she took a deep breath. In her nose, the mucosa is pale and swollen bilaterally. Her lungs have bilateral expiratory wheezing; respirations are 22 and PEF is 400. Her heart shows a normal sinus rhythm, with no murmurs or gallops; pulse is 72; and there is no cyanosis. P harmacotherapy for Mild Persistent Asthma Essay.

Diagnosis: Mild Persistent Asthma

  1. Discuss specific goals of pharmacotherapy for treating M. L.’s mild persistent asthma.
  2. Discuss the drug therapy a CNP would likely prescribe and why.
  3. Discuss the parameters for monitoring the success of the therapy.
  4. Discuss age-appropriate health promotion recommendations you would consider for M. L.


Pharmacotherapy for Mild Persistent Asthma Essay